Live Breaking News & Updates on Staining Is Frequent

Stay updated with breaking news from Staining is frequent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on. ....

United States , New York , San Diego , Kimberly Blackwell , Mark Lackner , Program Updates , Exchange Commission , Zentalis Pharmaceuticals Inc , Translational Sciences , Globenewswire Inc , Genentech Oncology Early Stage Biomarker Group , Development Expenses , Pharmaceuticals Inc , American Association For Cancer Research , Zentalis Pharmaceuticals , Translational Officer , Chief Scientific Officer , Chief Executive Officer , Chief Translational Officer , New Drug Application , Cancer Research , Special Conference , Staining Is Frequent , Prior Platinum Treatment , High Grade Serous Ovarian , Ovarian Cancer ,